Table 1. Laboratory studies from patient 1.
| Test | Result | Reference Range |
| SARS-CoV-2 RNA RT PCR | Negative | Negative |
| Anti-HCV (rapid) | Non-Reactive | — |
| HbsAg (rapid) | Non-Reactive | — |
| HIV (rapid) | Non-Reactive | — |
| Random blood glucose (non-fasting) | 130 | <140 mg/dL |
| CSF Studies | ||
| CSF description | 5 mL, clear, pale yellow | — |
| CSF Glucose | 66 | 40-70 mg/dL |
| CSF Protein | 17.3 | 15-45 mg/dL |
| Complete Blood Count | ||
| Hemoglobin | 15.3 | 13-17 g/dL |
| Total Leukocyte Count | 8.1 | 4-10 x 103/uL |
| RBC Count | 5.35 | 4.5-5.5 x 106/uL |
| ESR | 14 | mm/hr |
| Packed Cell Volume | 43.6 | 40-42% |
| Mean Corpuscular Volume | 81.5 | 83-101 fl |
| Mean Corpuscular Hemoglobin | 28.7 | 27-32 pg |
| MCHC | 35.2 | 31.5-34.5 g/dL |
| RDW | 13.4 | 11-16% |
| Platelet | 2.11 | 1.5-4 Lakhs/cumm |
| MPV | 8.6 | fl |
| Neutrophils | 65 | 40-80% |
| Lymphocytes | 28 | 20-40% |
| Monocytes | 5 | 2-10% |
| Eosinophils | 2 | 1-6% |
| PT/PT-INR | ||
| PT | 15.8 | 11-15 seconds |
| Control | 13.3 | seconds |
| INR | 1.18 | seconds |
| Liver Function Test/Profile-serum | ||
| Total Bilirubin | 0.2 mg/dL | 0.2-1 mg/dL |
| Direct Bilirubin | 0.1 mg/dL | 0-0.2 mg/dL |
| Indirect Bilirubin | 0.1 mg/dL | 0-1 mg/dL |
| Total Protein | 8 g/dL | 6.3-8.2 g/dL |
| Albumin | 4.3 g/dL | 3.5-5 g/dL |
| Globulin | 3.7 g/dL | 2-3.5 g/dL |
| A/G Ratio serum | 1.16 | 1.3-2 |
| SGOT/AST | 14 U/L | 5-40 U/L |
| SGPT/ALT | 34 U/L | 5-40 U/L |
| Alkaline Phosphatase | 170 U/L | 46-116 U/L |
| GGT-serum | 54 U/L | 5-85 U/L |
| Renal Profile-serum | ||
| Urea | 32 mg/dL | 15-39 mg/dL |
| Creatinine-serum | 0.72 mg/dL | 0.5-1.3 mg/dL |
| Uric Acid | 3.6 mg/dL | 2.5-7.5 mg/dL |
| Sodium (Na+) serum | 140 mEq/L | 135-145 mEq/L |
| Potassium (K+) serum | 4.3 mEq/L | 3.5-5.1 mEq/L |
| Chloride (Cl-) serum | 105 mEq/L | 98-107 mEq/L |
| Calcium serum | 9.3 mg/dL | 8.5-10.1 mg/dL |
| Phosphorus serum | 4.1 mg/dL | 2.5-4.5 mg/dL |